...
机译:Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination
Momelotinib; Citarinostat; HDAC inhibitor; JAK 1; 2 inhibitor; Lymphoid malignancies; Synergistic combination;